Autoimmune thyroiditis as a risk factor for stroke
A historical cohort study

ABSTRACT

Objective: To investigate the effect of autoimmune thyroiditis (AIT) on risk of stroke and to assess whether any increased risk (1) varied by AIT duration, and (2) was independent of classic cardiovascular risk factors.

Methods: This was a large historical cohort study using data from The Health Improvement Network Database. Rates of first stroke during follow-up in thyroxine-treated patients with AIT (n = 34,907) were compared with those in matched individuals without AIT (n = 149,632) using random-effects Poisson regression models.

Results: There was strong evidence for a slightly increased risk of stroke in patients with AIT (adjusted rate ratio = 1.10, 95% confidence interval: 1.01–1.20). The observed increase was partly independent of cardiovascular risk factors. Higher effect sizes were identified in the first year after AIT diagnosis (rate ratio = 1.33, 95% confidence interval: 1.14–1.56) but not in the long-term, consistent with a residual effect of hypothyroidism.

Conclusion: Our results support the hypothesis of a slightly increased risk of stroke in patients with AIT. The higher effect size found soon after AIT diagnosis suggests an increased cardiovascular risk due to thyroid-hormone deficiency rather than a cumulative effect of autoimmune pathology. Better screening and early treatment of patients with asymptomatic hypothyroid AIT could help reduce excess risk of stroke in the first year after diagnosis.

Neurology® 2014;82:1643–1652

GLOSSARY

AF = atrial fibrillation; AIT = autoimmune thyroiditis; BMI = body mass index; CHD = coronary heart disease; CHF = congestive heart failure; CI = confidence interval; RR = rate ratio; THIN = The Health Improvement Network.
These uncertainties have led to calls for large cohort studies to investigate the association between AIT and cerebrovascular disease. The primary objective of our study was to assess the effect of AIT on risk of stroke and TIA using a large dataset derived from UK primary care records. Secondary objectives were to examine to what extent any effect of AIT on cerebrovascular disease (1) was independent of classic cardiovascular risk factors, and (2) could be attributable to thyroid hormone deficiency or autoimmune pathology.

METHODS Study design and study population. This was a historical cohort study using data from The Health Improvement Network (THIN) database. THIN is a population-based database of electronic health records of approximately 6 million patients from more than 300 general practices in the United Kingdom. THIN has been validated for a wide range of medical conditions, including stroke, and individuals contributing data to THIN are representative of the UK population. Data available include prescribed medications, medical diagnoses, lifestyle conditions, demographic/personal information, and feedback from specialist appointments and hospital admissions. The present study population was a subset of a larger THIN study, in which patients with an autoimmune disease enrolled in THIN between 1987 and 2007 had each been matched by age, sex, and general practice to up to 6 individuals without any autoimmune disease.

Exposure and outcome. AIT was the exposure of interest; unexposed individuals comprised patients without AIT (or any other autoimmune disease) who had been matched on age, sex, and general practice to the patients with AIT in the original THIN dataset. The outcome of interest was first-ever stroke (including ischemic and hemorrhagic) or TIA during follow-up. Exposure and outcome were defined using prespecified Read code lists (appendix e-1 on the Neurology® Web site at Neurology.org).

Study period. Start of follow-up for individuals with AIT and their unexposed counterparts was the date of the first thyroxine prescription in the patients with AIT (the index date). End of follow-up was defined as the day of the outcome (stroke or TIA) or end of follow-up in THIN (death, transfer out, or the practice’s last data-collection date).

Eligibility criteria. Patients with AIT must have been first diagnosed with AIT during active follow-up in THIN and have been prescribed thyroxine during follow-up. Individuals with other causes for hypothyroidism (e.g., previous thyroidectomy) were excluded from analyses (figure 1). Diagnoses for past or ongoing conditions (including AIT) are sometimes recorded retrospectively in the first few months after a patient registers with a practice. To ensure that we enrolled incident cases, we excluded patients with AIT who were diagnosed during their first year of follow-up in THIN. All individuals (exposed and unexposed) who had a code for stroke or TIA before start of follow-up, or who were younger than 18 years, were not considered for inclusion. Also, because the unexposed (non-AIT) individuals had no other autoimmune disorders, individuals with AIT who had a preexisting or who developed a second autoimmune disorder were also excluded. Unexposed individuals had to be actively enrolled in THIN at the index date of their matched individual with AIT; to ensure that they were truly active, they had to have a consultation with the practice in the 6 months before or in the year after the index date of the patient with AIT.

Analysis. In the conceptual framework for this study (figure 2), cofactors were categorized as follows: (1) a priori confounders (sex, current age, general practice); (2) other potential confounders (smoking, alcohol consumption, calendar year, time in study); and (3) factors that could be either confounders or on the causal pathway from AIT to stroke, depending on whether they occurred before or after AIT diagnosis (figure 2B). Missing data for smoking, alcohol, and body mass index (BMI) were treated using the missing indicator method. An individually matched analysis is not needed in matched cohort studies, but inclusion of the matched variables in a multivariable analysis is advisable; this also addressed any imbalances between exposed and unexposed patients regarding these variables after the application of exclusion criteria.

Statistical analyses were conducted using Stata 11 (StataCorp, College Station, TX). Baseline characteristics were compared using cross-tabulation, means or medians as appropriate, and chi-square tests, 2-sided t tests, and Wilcoxon rank-sum tests. Main analyses were performed using random-effects multivariable Poisson regression models allowing for clustering within general practice. Four different models were built. The first was adjusted for sex and current age. In the second model, we assessed potential confounding by smoking, alcohol consumption, calendar year, and time in study, introducing these variables sequentially into the model and retaining them if they changed the effect estimate of AIT on stroke incidence appreciably. The third model additionally assessed risk factors (hypertension, AF, hyperlipidemia, diabetes, CHD, congestive heart failure [CHF], and BMI) that were present at the index date and could therefore also confound the association between AIT and stroke. In the final model, we examined time-updated values of these factors for individuals who developed these conditions during follow-up to assess potential causal pathways between diagnosed AIT and stroke. We applied this analysis strategy to 2 main outcomes, first stroke, then stroke or TIA. In all models, standard errors were examined for evidence of colinearity, and p values were obtained using likelihood ratio tests.

We investigated effect modification by AIT duration as a proxy for the effects of hypothyroidism (likely to be evident in the early stages of disease, before adequate thyroxine replacement) vs the possible cumulative effect of autoimmune (long-term increased risk, likely to occur later during follow-up). We also investigated effect modification by age (=<60, 60–80, >80 years) and performed several sensitivity analyses. First, analyses were repeated starting follow-up at the date of first AIT code instead of first thyroxine script. Second, cardiovascular conditions present among patients with AIT at diagnosis could be early mediating factors for stroke rather than a confounding variable; to assess their importance, we performed subgroup analyses for individuals without a history of any cardiovascular disease–related conditions at baseline.

Standard protocol approvals, registrations, and patient consents. Ethics approval was obtained from the South-East Multicentre Research Ethics Committee and from the London School of Hygiene and Tropical Medicine Ethics Committee.

RESULTS In total, 184,539 eligible individuals from 287 general practices were included in this study, of whom 34,907 had AIT (figure 2) and 149,632 had no evidence of AIT. Individuals with AIT were slightly older than individuals without AIT (median
59.8 vs 57.0 years), were followed up for longer (median 3.2 vs 3.0 years), and a slightly higher proportion was female (81.5% vs 80.0%; table 1). Current smoking and heavy drinking were less common among those with AIT. For cardiovascular risk factors, individuals with AIT were more likely to have been diagnosed with hypertension, diabetes, hyperlipidemia, CHD, or CHF at baseline (all \( p < 0.001 \)). This pattern remained after adjusting for the slight age and sex imbalances (data not shown).

Individuals with AIT had a 13% increased rate of stroke compared with individuals without AIT after adjusting for current age and sex and allowing for clustering in practice (model 1, table 2). The increased risk was very similar (rate ratio [RR] = 1.14, 95% confidence interval [CI]: 1.04–1.24, \( p = 0.003 \)) after adjusting for alcohol and smoking (model 2) and was not affected by the duration of follow-up or calendar year. The RR decreased slightly to 1.10 (95% CI: 1.01–1.20, model 3) after adjusting additionally for cardiovascular risk factors present at baseline (hypertension, hyperlipidemia, AF, and BMI) and was not further changed by consideration of existing diabetes, CHD, and CHF.

Individuals with AIT had an increased risk of developing CHD, hyperlipidemia, CHF, and diabetes during follow-up compared with unexposed individuals (table e-1), but not hypertension or AF. After
adjusting for these potential mediating factors between AIT and stroke, the RR for stroke was further reduced to 1.06 (95% CI: 0.97–1.15, model 4). Effect sizes were slightly higher for all models when the outcome definition was expanded to both stroke and TIA (table 2).

There was evidence that the effect of AIT on stroke varied with duration of disease ($p_{\text{interaction}} = 0.078$, figure 3). The effect of AIT on stroke was largest in the first year after diagnosis (RR = 1.33, 95% CI: 1.14–1.56) and was increased both in the first 6 months (RR = 1.44, 95% CI: 1.17–1.78) and 7 to 12 months after start of treatment (RR = 1.22, 95% CI: 1.02–1.55). Subsequent RRs were stable with all 95% CIs including 1.0. Similar results were obtained for analyses using TIA or stroke and TIA alone as the outcome. There was no evidence that the effect of AIT varied with age ($p_{\text{interaction}} = 0.516$).

All sensitivity analyses showed results compatible to those obtained from the main analyses (data not shown).

**DISCUSSION**

Our study provides strong evidence for a slightly increased risk of stroke in patients with AIT, particularly in the first year after AIT diagnosis. Our analyses indicated that people with AIT were more likely to develop hyperlipidemia, CHD, and CHF, adding evidence to previous discussions about whether AIT is associated with these factors, and that some, but not all, of the increased risk of stroke among patients with AIT was mediated via these classic cardiovascular risk factors.14

Few previous studies have focused on potential associations between hypothyroidism or AIT and stroke. Our systematic review identified 7 studies, which showed effect sizes ranging from 0.8 to 1.6 (table e-2). All of these studies except for the Scottish study from 2006 were small and had effect estimates with wide CIs that overlapped with those from the present study. Other methodologic limitations of previous studies included overadjustment for variables that could be mediators of increased stroke risk, and residual confounding (for example, the Scottish study...
### Table 1  Baseline characteristics of individuals with and without AIT

|                      | AIT (n = 34,907), median (IQR) | No AIT (n = 149,632), median (IQR) | p Value* |
|----------------------|---------------------------------|-------------------------------------|----------|
| Age at entry, y      | 59.8 (47.2–72.7)                | 57.0 (44.0–70.6)                    | <0.001   |
| Years of follow-up   | 3.3 (1.6–6.1)                   | 2.9 (1.4–5.3)                       | <0.001   |

|                      | AIT (n = 34,907) | No AIT (n = 149,632) | p Value* |
|----------------------|------------------|----------------------|----------|
| Sex                  |                  |                      |          |
| Male                 | 6,472            | 29,817               | 18.5     |
| Female               | 28,435           | 119,815              | 81.5     |
| Hypertension         |                  |                      | <0.001   |
| No                   | 23,935           | 113,102              | 68.6     |
| Yes                  | 10,972           | 36,530               | 31.4     |
| Diabetes             |                  |                      | <0.001   |
| No                   | 32,713           | 143,129              | 93.7     |
| Yes                  | 2,194            | 6,503                | 6.3      |
| CHD                  |                  |                      | <0.001   |
| No                   | 31,024           | 139,062              | 88.9     |
| Yes                  | 3,883            | 10,570               | 11.1     |
| AF                   |                  |                      | <0.001   |
| No                   | 33,444           | 146,572              | 95.8     |
| Yes                  | 1,463            | 3,060                | 4.2      |
| CHF                  |                  |                      | <0.001   |
| No                   | 33,532           | 146,442              | 96.2     |
| Yes                  | 1,375            | 3,190                | 3.8      |
| Hyperlipidemia       |                  |                      | <0.001   |
| No                   | 30,002           | 135,794              | 86.0     |
| Yes                  | 4,905            | 13,838               | 14.0     |
| Smoking status       |                  |                      | <0.001   |
| Non                  | 12,869           | 55,441               | 36.9     |
| Ex                   | 10,590           | 36,393               | 30.3     |
| Current              | 10,377           | 49,886               | 29.7     |
| Unknown              | 1,071            | 7,912                | 3.1      |
| Alcohol consumption  |                  |                      | <0.001   |
| None                 | 6,901            | 25,236               | 19.8     |
| Ex                   | 466              | 1,503                | 1.3      |
| Rare                 | 21,782           | 90,814               | 62.4     |
| Moderate             | 1,653            | 9,450                | 4.7      |
| Heavy                | 156              | 994                  | 0.5      |
| Unknown              | 3,949            | 21,635               | 11.3     |
| BMI, kg/m²           |                  |                      | <0.001   |
| <20                  | 1,352            | 8,523                | 3.9      |
| 20–24.9              | 9,152            | 49,231               | 26.2     |
| 25–30                | 10,985           | 43,093               | 31.5     |
| >30                  | 9,166            | 25,760               | 26.3     |
| Unknown              | 4,252            | 23,025               | 12.2     |

Continued
lacked information on smoking, alcohol use, and medication history).\(^7\)\(^{12,22-26}\) Also, studies included individuals with a history of stroke. This could explain their slightly higher effect estimates, because thyroid hormone status is often assessed at stroke units, resulting in better AIT ascertainment in individuals with a stroke history (who are at higher risk of a subsequent stroke). Three of the studies were conceptually different from this study because they used asymptomatic patients identified as hypothyroid by laboratory tests who were mostly untreated with thyroxine.\(^7\)\(^{12,23}\)

We found differences between individuals with and without AIT in the prevalence of traditional cardiovascular risk factors at baseline. Individuals with AIT were more likely to have AF and hypertension at baseline compared to those without AIT; however, they were not at increased risk of developing these conditions during follow-up. This finding is consistent with that from a recent population-based study from Germany, which reported that hypothyroidism was associated with prevalent but not incident hypertension.\(^33\) Hypertension and AF may not be on the causal pathway between AIT and stroke, although the differences we observed at baseline could represent early changes induced by undiagnosed AIT. Differences in AF (and possibly hypertension) at baseline between individuals with AIT and those without could also be explained by differences in ascertainment of AIT, if individuals with AF were more likely to have thyroid-stimulating hormone levels measured.

Our main model of interest, adjusted for these baseline variables, is based on the assumption that pathologic mechanisms on the causal pathway to stroke did not start until after AIT diagnosis and initiation of thyroxine treatment. Thus, these factors were treated as potential confounders. However, it is likely that the date of AIT diagnosis/start of treatment did not accurately capture start of disease. Given that patients with AIT often present with nonspecific symptoms, diagnosis of AIT can be delayed. Thus, it is plausible that cardiovascular causal processes could have started before formal diagnosis of AIT. If so, model 3 (which adjusted for these variables) may have provided a conservative estimate of relative stroke risk, and model 2 might provide an estimate closer to the true effect. However, the effect estimates produced by these 2 models were similar; also, the sensitivity analysis excluding all individuals with cardiovascular disease–related conditions at baseline showed results similar to the main analysis.

Our finding of a higher effect of AIT on stroke risk in the first year after diagnosis is compatible with the hypothesis of increased cerebrovascular risk in patients with AIT due to prediagnosis hypothyroidism and the time taken to reduce this risk after thyroid hormone replacement. There was no evidence for an increasing effect with increased length of follow-up (a possible proxy for a long-term effect mediated by autoimmune processes). An alternative explanation is that the observed effect of AIT on stroke was caused by thyroxine treatment because thyroxine can have a procoagulant effect.\(^34\) However, if the observed effect was due to thyroxine, we might expect to have seen the excess stroke risk restricted to the period soon after start of treatment, whereas the risk remained increased 6 to 12 months after diagnosis in our study. Moreover, a thyroxine-mediated effect might also be expected to generate short-term differences in incidence of AF between patients with AIT and individuals without AIT because thyroxine in high doses can induce AF; this was not the case. Nevertheless, we cannot exclude that some of the effect attributed to hypothyroidism could have been due to thyroxine, and we were unable to examine this formally because all patients with AIT received thyroxine.

This study has several strengths. We used a considerably larger study population than all previous studies, and thus had greater power to ascertain effect estimates. We had information on a variety of potential confounding factors that could be considered in the analysis. Unlike previous studies, we excluded...
individuals with a history of stroke, avoiding introduction of bias. Moreover, excluding people with other autoimmune diseases from our study population enabled us to observe the effect of AIT unmodified by other autoimmune disorders. This might not have been the case in other studies, because patients with AIT are at higher risk of acquiring other autoimmune disorders, some of which (e.g., rheumatoid arthritis, type 1 diabetes) are associated with considerable increased risk of cardio- and cerebrovascular disease.\(^{16,35}\)

Potential limitations of our study also need consideration. Almost all noniatrogenic hypothyroidism in the United Kingdom is due to AIT, and we excluded individuals who had other reasons for hypothyroidism. However, our Read code list included nonspecific hypothyroidism codes, which increased sensitivity of AIT diagnosis but could have included a few non-AIT cases. Because hypothyroidism can remain undiagnosed for an unspecified time, some patients with AIT could have been misclassified as non-AIT.

### Table 2: Multivariable analysis of the effect of AIT on stroke and TIA adjusted for covariates (and allowing for clustering in practice)

| Events | Person-years at-risk (in 1,000) | Model 1 \(^a\) | Model 2 \(^b\) | Model 3 \(^c\) | Model 4 \(^d\) |
|--------|---------------------------------|----------------|----------------|----------------|----------------|
| Stroke | No AIT                          | 2,254          | 568.2          | 0.005          | 0.003          | 0.029          | 0.191          |
|        | AIT                             | 711            | 147.0          | 1.13 (1.04-1.23) | 1.14 (1.04-1.24) | 1.10 (1.01-1.20) | 1.06 (0.97-1.15) |
| TIA    | No AIT                          | 1,423          | 563.4          | 1.002          | 1.002          | 1.003          | 1.033          |
|        | AIT                             | 482            | 145.3          | 1.18 (1.06-1.30) | 1.17 (1.05-1.30) | 1.16 (1.05-1.29) | 1.13 (1.01-1.25) |
| Stroke or TIA | No AIT | 3,312 | 558.9 | 1.0 | <0.001 | 1.0 | <0.001 | 1.0 | <0.001 | 1.0 | 0.010 |
|        | AIT                             | 1,065          | 143.5          | 1.14 (1.06-1.22) | 1.16 (1.08-1.24) | 1.13 (1.06-1.22) | 1.10 (1.02-1.18) |

Abbreviations: AIT = autoimmune thyroiditis; CI = confidence interval; RR = rate ratio.

\(^a\) Adjusted for current age and sex only.

\(^b\) Adjusted for current age, sex, alcohol, smoking; calendar year and time in the study did not further change the effect.

\(^c\) Adjusted for current age, sex, alcohol, smoking, hypertension, atrial fibrillation, hyperlipidemia, and body mass index (all at baseline). Diabetes, coronary heart disease, and congestive heart failure status at baseline did not further change the effect.

\(^d\) Adjusted for current age, sex, alcohol, smoking, hypertension, atrial fibrillation, hyperlipidemia, and body mass index (time-updated). Diabetes, coronary heart disease, and congestive heart failure did not further change the effect.

\(^e\) Using likelihood ratio tests.
Does L-thyroxine prevent or cause stroke in hypothyroidism?

The association between overt hypothyroidism and atherosclerotic risk factors, especially hypertension and dyslipidemia, is clear. To date, only a few small and methodologically flawed epidemiologic studies have investigated the relationship between hypothyroidism and stroke, precluding definitive conclusions. In the current issue of Neurology®, Karch and Thomas present a large well-designed case-control study investigating this relationship. They compared 34,907 patients with autoimmune thyroiditis on treatment with L-thyroxine and 149,632 matched individuals without autoimmune thyroiditis from a UK primary care electronic health record system. They found a slight increase in the risk of stroke in patients with autoimmune thyroiditis (adjusted relative risk = 1.10, 95% confidence interval: 1.01–1.20) compared with controls. Some of this increased risk of stroke was independent of cardiovascular risk factors.

Overall, these data suggest that thyroid hormone deficiency may cause stroke independent of atherosclerosis and hypertension. This raises the question of the mechanism of the observed association. Some patients with overt hypothyroidism and bleeding complications have an acquired von Willebrand syndrome, suggesting an effect of thyroid hormones on von Willebrand factor synthesis. This study defined stroke as ischemic or hemorrhagic, therefore some of the difference may be explained by more bleeding events. Alternatively, L-thyroxine treatment and not low thyroid hormones per se could explain the increased risk. L-Thyroxine increases coagulation factor levels, in particular von Willebrand factor and factor VIII, and inhibits fibrinolysis in a dose-dependent manner. This may lead to a temporarily increased ischemic stroke risk in patients with autoimmune thyroiditis who have a higher prevalence of obesity, hypertension, diabetes, and atrial fibrillation. This theory is supported by the observation of higher risk during the first year after diagnosis (relative risk = 1.33, 95% confidence interval: 1.14–1.56) compared with long-term follow-up.

Future epidemiologic studies should investigate stroke risk not only after but also before L-thyroxine start and should discriminate between ischemic and hemorrhagic stroke.

Comment: Does L-thyroxine prevent or cause stroke in hypothyroidism?

The association between overt hypothyroidism and atherosclerotic risk factors, especially hypertension and dyslipidemia, is clear. To date, only a few small and methodologically flawed epidemiologic studies have investigated the relationship between hypothyroidism and stroke, precluding definitive conclusions. In the current issue of Neurology®, Karch and Thomas present a large well-designed case-control study investigating this relationship. They compared 34,907 patients with autoimmune thyroiditis on treatment with L-thyroxine and 149,632 matched individuals without autoimmune thyroiditis from a UK primary care electronic health record system. They found a slight increase in the risk of stroke in patients with autoimmune thyroiditis (adjusted relative risk = 1.10, 95% confidence interval: 1.01–1.20) compared with controls. Some of this increased risk of stroke was independent of cardiovascular risk factors.

Overall, these data suggest that thyroid hormone deficiency may cause stroke independent of atherosclerosis and hypertension. This raises the question of the mechanism of the observed association. Some patients with overt hypothyroidism and bleeding complications have an acquired von Willebrand syndrome, suggesting an effect of thyroid hormones on von Willebrand factor synthesis. This study defined stroke as ischemic or hemorrhagic, therefore some of the difference may be explained by more bleeding events. Alternatively, L-thyroxine treatment and not low thyroid hormones per se could explain the increased risk. L-Thyroxine increases coagulation factor levels, in particular von Willebrand factor and factor VIII, and inhibits fibrinolysis in a dose-dependent manner. This theory is supported by the observation of higher risk during the first year after diagnosis (relative risk = 1.33, 95% confidence interval: 1.14–1.56) compared with long-term follow-up.

Future epidemiologic studies should investigate stroke risk not only after but also before L-thyroxine start and should discriminate between ischemic and hemorrhagic stroke.

1. Karch A, Thomas SL. Autoimmune thyroiditis as a risk factor for stroke: a historical cohort study. Neurology 2014;82:1643–1652.
2. Stuijver DJ, Piantanida E, van Zaane B, et al. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. Haemophilia Epub 2013 Oct 14.
3. Van Zaane B, Squizzato A, Debeij J, et al. Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. J Thromb Haemost 2011;9:1816–1824.

Alessandro Squizzato, MD, PhD
Victor E.A. Gerdes, MD, PhD

From the Research Center on Thromboembolic Disorders and Antithrombotic Therapies (A.S.), Department of Clinical Medicine, University of Insubria, Varese, Italy; and Department of Internal Medicine (V.E.A.G.), Slotervaart Hospital, Amsterdam, the Netherlands.

Disclosure: The authors report no disclosures. Go to Neurology.org for full disclosures.
AUTHOR CONTRIBUTIONS

S.T. conceived the study. Both authors developed the study design. A.K. conducted the data management, analyzed the data, and wrote the manuscript, with contributions from S.T. Both authors interpreted the findings, contributed to critical revision of the manuscript for important intellectual content, and approved the final version.

ACKNOWLEDGMENT

The authors thank Ian Douglas for providing the original medical and therapy code lists for various cofactors.

STUDY FUNDING

Supported by a project grant from the Wellcome Trust (079482/Z/06/Z) and by a postgraduate fellowship of the DAAD (German Academic Exchange Service, for A.K.).

STUDY FUNDING

Supported by a project grant from the Wellcome Trust (079482/Z/06/Z) and by a postgraduate fellowship of the DAAD (German Academic Exchange Service, for A.K.).

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received June 25, 2013. Accepted in final form January 16, 2014.

REFERENCES

1. Flynn RW, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004;89:3879–3884.
2. McGrogan A, Seaman HE, Wright JW, de Vries CS. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrinol 2008;69:687–696.
3. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793–803.
4. Weetman A. Thyroid disease. In: Rose N, Mackay I, editors. The Autoimmune Diseases. San Diego: Academic Press; 2006.
5. Aho K, Gordin A, Palouso T, et al. Thyroid autoimmunity and cardiovascular diseases. Eur Heart J 1984;5:43–46.
6. Bauer DC, Rodondi N, Stone KL, Hillier TA. Thyroid hormone use, hyperthyroidism and mortality in older adults. Am J Med 2007;120:343–349.
7. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006;295:1033–1041.
8. Gasparotto J, van Exel E, de Czaen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA 2004;292:2591–2599.
9. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270–278.
10. Imamura M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hyperthyroidism. J Clin Endocrinol Metab 2004;89:3365–3370.
11. Parke JV, Maisonneuve P, Sheppard MC, Boyle P, Franklin JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861–865.
12. Rodondi N, Newman AB, Vintinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005;165:2460–2466.
13. Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996;6:155–160.
14. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832–845.
15. Diekman T, Lansburg PJ, Kastelein JJ, Wiersinga WM. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 1995;155:1490–1495.
16. Frosteard G. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005;25:1776–1785.
17. Morris JS, Boston AG, Jacques PF, Selhub J, Rosenberg JH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 2001;155:195–200.
18. Polikar R, Burger AG, Scherrer U, Niced P. The thyroid and the heart. Circulation 1993;87:1435–1441.
19. Saito I, Saruta T. Hypertension in thyroid disorders. Endocrinol Metab Clin North Am 1994;23:379–386.
20. Shah JH, Motto GS, Papapannes E, Williams GA. Insulin metabolism in hypothyroidism. Diabetes 1979;24:922–925.
21. Squirrato A, Gerdes VE, Brandjes DP, Boller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke 2005;36:2302–2310.
22. Dorr M, Empen K, Robinson DM, Wallaschofski H, Felix SB, Volzke H. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. Eur J Endocrinol 2008;159:145–152.
23. Flynn RW, MacDonald TM, Jung RT, Morris AD, Leese GP. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006;91:2159–2164.
24. Katakurum Gokrul B, Karatas M, Nebucha A, et al. Subclinical hypothyroidism, hyperhomocysteinemia and dyslipidemia: investigating links with ischemic stroke in Turkish patients. Neurol Res 2007;29:871–876.
25. Qureshi AI, Suri FK, Nasar A, Kimani JF, Divani AA, Giles WH. Free thyroxine index and risk of stroke: results from the National Health and Nutrition Examination Survey Follow-up Study. Med Sci Monit 2006;12:CR501–CR506.
26. Remmel KS, Wamahita A, Moore K, Gruenthal M. Acute ischemic stroke and hypothyroidism. J Ky Med Assoc 2006;104:191–193.
27. Ciccone MM, De Pergola G, Porcelli MT, et al. Increased carotid IMT in overweight and obese women affected by Hashimoto’s thyroiditis: an adiposity and autoimmune disease? BMJ Cardiovas Disord 2010;10:22.
28. Rooijman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011;27:174–182.
29. The Health Improvement Network. The Health Improvement Network [online]. Available at: http://www.thin.uk.com/. Accessed June 8, 2011.
30. Lewis JD, Schimann R, Bilker WB, Wang X, Stroom BL. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoeconimol Drug Saf 2007;16:393–401.
31. Ruizgomez A, Martin-Morino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in The Health Improvement Network.
32. Sjolander A, Greenland S. Ignoring the matching variables in cohort studies: when is it valid and why? Stat Med 2013;32:4696–4708.

33. Ittermann T, Tiller D, Meisinger C, et al. High serum TSH levels are associated with current but not with incident hypertension. Thyroid 2013;23:955–963.

34. Van Zaane B, Squizzato A, Debeij J, et al. Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. J Thromb Haemost 2011;9:1816–1824.

35. Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology 2006;17:202–217.

36. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611–2618.

37. Saito T, Masuda Y, Otsuka T, Endo M, Murayama H. Proceedings: changes in renin-angiotensin system in essential hypertension and thyroid diseases [in Japanese]. Nihon Naibunpi Gakkai Zasshi 1974;50:438.

38. Manfredi E, van Zaane B, Gerdes VE, Brandjes DP, Squizzato A. Hypothyroidism and acquired von Willebrand’s syndrome: a systematic review. Hemophilia 2008;14:423–433.
Autoimmune thyroiditis as a risk factor for stroke: A historical cohort study
André Karch and Sara L. Thomas

Neurology 2014;82;1643-1652 Published Online before print April 9, 2014
DOI 10.1212/WNL.0000000000000377

This information is current as of April 9, 2014
